Biosimilars Program Will Be “Under-Resourced” In Early Years As Industry Grows
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER Director Janet Woodcock says user fee revenue will increase slowly, in part because some fees will not produce much revenue until the biosimilar industry expands.
You may also be interested in...
BsUFA Revenue Missed Estimates Again In FY2019
US FDA said that total BsUFA obligations also decreased compared to estimates, but maintains optimism about future revenue increases.
Biosimilar User Fee Revenue Missed Estimates Again In FY 2019, Spending Reduced
US FDA said that total BsUFA obligations also decreased compared to estimates, but maintains optimism about future revenue increases.
Biosimilar User Fee Collections Drop Below Estimates, But FDA Is Not Worried
The agency hopes application volume increases, but warns the biosimilar user fee revenue will remain volatile.